MARIA MERCEDES
DURAN DOMINGUEZ
PROFESOR CONTRATADO DOCTOR
University of Toronto
Toronto, CanadáPublicacions en col·laboració amb investigadors/es de University of Toronto (13)
2020
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
2017
-
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Nature Genetics, Vol. 49, Núm. 5, pp. 680-691
2014
-
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers
Breast Cancer Research, Vol. 16
-
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
PLoS Genetics, Vol. 10, Núm. 4
2013
2012
-
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Cancer Epidemiology Biomarkers and Prevention, Vol. 21, Núm. 4, pp. 645-657
-
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
Human Mutation, Vol. 33, Núm. 4, pp. 690-702
2011
-
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
Breast Cancer Research, Vol. 13, Núm. 6
-
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
Human Genetics, Vol. 130, Núm. 5, pp. 685-699
-
International distribution and age estimation of the Portuguese BRCA2 c.156-157insAlu founder mutation
Breast Cancer Research and Treatment, Vol. 127, Núm. 3, pp. 671-679
2010
-
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: Implications for risk prediction
Cancer Research, Vol. 70, Núm. 23, pp. 9742-9754
-
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer
PLoS Genetics, Vol. 6, Núm. 10, pp. 1-12
2009
-
The TP53 Arg72Pro and MDM2 309GT polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
British Journal of Cancer, Vol. 101, Núm. 8, pp. 1456-1460